Treatment of Vertigo
For benign paroxysmal positional vertigo (BPPV)—the most common cause of vertigo—perform the canalith repositioning procedure (Epley maneuver) immediately; do NOT prescribe vestibular suppressant medications routinely. 1
BPPV Treatment Algorithm
First-Line Treatment: Canalith Repositioning Procedure
- Perform the Epley maneuver (or refer to someone who can) for posterior canal BPPV—this is a strong recommendation based on high-quality evidence 1
- The procedure physically repositions displaced otoconia (calcium crystals) from the semicircular canals back to the utricle
- Success rates are high, with symptom resolution in most patients
- Do NOT impose postural restrictions after the procedure (sleeping upright, avoiding certain positions)—these restrictions provide no additional benefit 1
Alternative Initial Approach
- Observation with follow-up is acceptable for up to 1 week, as BPPV can spontaneously resolve in approximately 20% of patients by 1 month 1, 2
- However, this delays symptom relief and increases fall risk, so repositioning is preferred
Adjunctive Options
- Vestibular rehabilitation (self-administered or clinician-guided) may be offered as an option 1
- Brandt-Daroff exercises can be taught for home use 1
What NOT to Do
- Do NOT routinely prescribe vestibular suppressants (antihistamines like meclizine, benzodiazepines) for BPPV—this is a strong recommendation against their use 1
- These medications do not address the underlying mechanical problem and cause sedation, increasing fall risk
- Do NOT order imaging (MRI, CT) unless there are additional neurological signs inconsistent with BPPV 1
- Do NOT order vestibular testing unless symptoms suggest something beyond BPPV 1
Reassessment
- Reassess within 1 month to document resolution or persistence 1
- If symptoms persist, re-evaluate for unresolved BPPV (repeat maneuver) or consider alternative diagnoses 1
Recurrence Prevention
- For patients with low vitamin D levels, vitamin D and/or calcium supplementation reduces recurrence rates 2
- Risk factors include female sex, osteoporosis, migraine, head trauma, and high cholesterol 2
Ménière's Disease Treatment
For Ménière's disease (episodic vertigo with unilateral hearing loss, tinnitus, and aural fullness), treatment follows a stepwise approach from least to most aggressive 3:
Conservative Management
- Low-sodium diet (1500-2300 mg daily) 3
- Limit alcohol and caffeine 3
- Diuretics to reduce endolymphatic fluid 3
Acute Symptom Management
- Antivertigo medications for acute attacks 3
- Antihistamines for associated symptoms 3
- Betahistine (where available) to increase inner ear vasodilation 3
Interventional Options (for refractory cases)
Surgical Options (last resort)
- Endolymphatic sac decompression (hearing-sparing) 3
- Vestibular nerve section (hearing-sparing) 3
- Labyrinthectomy (hearing-ablative) 3
Vestibular Neuritis Treatment
For acute vestibular neuritis (sudden-onset vertigo without hearing loss):
- Vestibular suppressants (antihistamines, benzodiazepines) are appropriate for acute symptom relief in the first 48-72 hours 4
- Vestibular rehabilitation is essential for recovery 4
- Corticosteroids may be considered in the acute phase
Central Vertigo
For vertigo with neurological signs (diplopia, dysarthria, ataxia, focal weakness):
- Urgent neurological evaluation and imaging are mandatory 4, 5
- Treatment targets the underlying cause (stroke, demyelination, tumor)
- This represents a medical emergency
Critical Pitfalls to Avoid
Misdiagnosing BPPV and prescribing meclizine instead of performing the Epley maneuver—this is the most common error in primary care, occurring in 57% of cases while only 11% receive appropriate repositioning 6
Ordering unnecessary imaging for straightforward BPPV—if the Dix-Hallpike test is positive with characteristic nystagmus, imaging adds no value 1
Imposing postural restrictions after the Epley maneuver—patients can resume normal activities immediately 1
Missing central causes—always assess for "red flags" including sudden severe headache, focal neurological deficits, new-onset severe vertigo in vascular risk patients, or inability to walk 4, 5
Continuing vestibular suppressants beyond acute symptom control—these medications delay central compensation and prolong recovery 1, 4